Literature DB >> 34120127

Dynamic Serial Cytokine Measurements During Intravenous Ca-DTPA Chelation in Gadolinium Deposition Disease and Gadolinium Storage Condition: A Pilot Study.

Holden T Maecker1, Janet C Siebert2, Yael Rosenberg-Hasson1, Lorrin M Koran3, Miguel Ramalho, Richard C Semelka4.   

Abstract

PURPOSE: The aim of this study was to investigate the feasibility of measuring early changes in serum cytokine levels after intravenous diethylenetriaminepentaacetic acid (Ca-DTPA) chelation in patients manifesting either gadolinium deposition disease (GDD) or gadolinium storage condition (GSC) and the possible usefulness of this method in further research.
METHODS: Four patients with recent-onset GDD (≤1 year) and 2 patients with long-standing GSC (4 and 9 years) underwent chelation with intravenous bolus administration of Ca-DTPA. Multiple blood draws were performed to measure serum cytokines: at T = 0 (before Ca-DTPA injection) and 1, 5, 10, 30, 60 minutes, and 24 hours after Ca-DTPA injection. Patients rated the severity of GDD symptom flare at 24 hours. The 24-hour urine Gd amounts were measured prechelation and for the 24 hours after chelation. Serum samples were analyzed blind to whether patients had GDD or GSC but with knowledge of the time points characterizing each sample.
RESULTS: Urine samples for both GDD and GSC patients showed increases in Gd postchelation. All GDD patients experienced flare reactions postchelation; the 2 GSC patients did not. Two cytokines, EGF and sCD40L, peaked at 30 minutes postchelation in at least 4 of the 6 participants. Three cytokines, ENA78/CXCL5, EOTAXIN/CCL11, and LEPTIN, peaked at 24 hours in at least 4 of the 6 participants. Two participants were high outliers for a large number of cytokines across time points. No clear distinction between GDD and GSC was apparent from the cytokine patterns, although differences were present.
CONCLUSIONS: This pilot study describes precise temporal resolution (in the range of minutes) after a cytokine-inciting event. Select cytokines exhibited peak values at different time points. At this preliminary stage of investigation, peak cytokine release seems to reflect the amount of Gd mobilized rather than the severity of the patient symptomatic reaction. Too few subjects were studied to support statistical analysis between GDD and GSC groups, although differences were observed through visual data analysis.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 34120127      PMCID: PMC8664920          DOI: 10.1097/RLI.0000000000000803

Source DB:  PubMed          Journal:  Invest Radiol        ISSN: 0020-9996            Impact factor:   6.016


  24 in total

Review 1.  Pathophysiology of Inflammatory Bowel Diseases.

Authors:  John T Chang
Journal:  N Engl J Med       Date:  2020-12-31       Impact factor: 91.245

Review 2.  Gadolinium retention in the body: what we know and what we can do.

Authors:  Enrico Tedeschi; Ferdinando Caranci; Flavio Giordano; Valentina Angelini; Sirio Cocozza; Arturo Brunetti
Journal:  Radiol Med       Date:  2017-03-30       Impact factor: 3.469

3.  Incorporation of excess gadolinium into human bone from medical contrast agents.

Authors:  Thomas H Darrah; Jennifer J Prutsman-Pfeiffer; Robert J Poreda; M Ellen Campbell; Peter V Hauschka; Robyn E Hannigan
Journal:  Metallomics       Date:  2009-09-16       Impact factor: 4.526

Review 4.  Gadolinium tissue deposition in brain and bone.

Authors:  Nozomu Murata; Kiyoko Murata; Luis F Gonzalez-Cuyar; Kenneth R Maravilla
Journal:  Magn Reson Imaging       Date:  2016-10-05       Impact factor: 2.546

5.  Gadolinium-Based MRI Contrast Agents Induce Mitochondrial Toxicity and Cell Death in Human Neurons, and Toxicity Increases With Reduced Kinetic Stability of the Agent.

Authors:  Danielle V Bower; Johannes K Richter; Hendrik von Tengg-Kobligk; Johannes T Heverhagen; Val M Runge
Journal:  Invest Radiol       Date:  2019-08       Impact factor: 6.016

6.  The involvement of pro-inflammatory cytokines in nephrogenic systemic fibrosis - a mechanistic hypothesis based on preclinical results from a rat model treated with gadodiamide.

Authors:  T Steger-Hartmann; M Raschke; B Riefke; H Pietsch; M A Sieber; J Walter
Journal:  Exp Toxicol Pathol       Date:  2009-01-07

7.  Gadolinium Retention in the Central and Peripheral Nervous System: Implications for Pain, Cognition, and Neurogenesis.

Authors:  Safia M Alkhunizi; Marc Fakhoury; Wassim Abou-Kheir; Nada Lawand
Journal:  Radiology       Date:  2020-08-18       Impact factor: 11.105

8.  Gadolinium in Humans: A Family of Disorders.

Authors:  Richard C Semelka; Miguel Ramalho; Mamdoh AlObaidy; Joana Ramalho
Journal:  AJR Am J Roentgenol       Date:  2016-05-25       Impact factor: 3.959

9.  Acute Chelation Therapy-Associated Changes in Urine Gadolinium, Self-reported Flare Severity, and Serum Cytokines in Gadolinium Deposition Disease.

Authors:  Holden T Maecker; Janet C Siebert; Yael Rosenberg-Hasson; Lorrin M Koran; Miguel Ramalho; Richard C Semelka
Journal:  Invest Radiol       Date:  2021-06-01       Impact factor: 10.065

10.  Exposure of Macrophages to Low-Dose Gadolinium-Based Contrast Medium: Impact on Oxidative Stress and Cytokines Production.

Authors:  Te-I Weng; Huang Jen Chen; Chen-Wen Lu; Yu-Chin Ho; Jia-Lun Wu; Shing-Hwa Liu; Jong-Kai Hsiao
Journal:  Contrast Media Mol Imaging       Date:  2018-12-02       Impact factor: 3.161

View more
  1 in total

Review 1.  Use of Real-Life Safety Data From International Pharmacovigilance Databases to Assess the Importance of Symptoms Associated With Gadolinium Exposure.

Authors:  Imran Shahid; Alvin Joseph; Eric Lancelot
Journal:  Invest Radiol       Date:  2022-04-26       Impact factor: 10.065

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.